FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315300447> ?p ?o ?g. }

• W2315300447 endingPage "121" @default.
• W2315300447 startingPage "121.1" @default.
• W2315300447 abstract "Background Recently, the European Medicines Agency approved a biosimilar to infliximab, CT-P13. Biosimilars are not only required to have biochemical and pharmacokinetics (PK) equivalence, but also must demonstrate similarity in their therapeutic effectiveness, safety and immunogenicity. The PLANETAS was a randomized double-blind, parallel group study for demonstrating PK equivalence between biosimilar infliximab (CT-P13) and innovator infliximab (INX) in patients with ankylosing spondylitis (AS). Objectives To compare disease activity, disability and mobility indices of CT-P13 and INX and to assess the effect of anti-drug antibody (ADA) on the observed indices in patients participated in the PLANETAS. Methods In the PLANETAS, key secondary endpoints captured the clinical measures of disease activity via ASAS20/40 and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), disability via the Bath Ankylosing Spondylitis Functional Index (BASFI) and mobility via the Bath Ankylosing Spondylitis Metrology Index (BASMI). The Student9s t test was used to compare mean change of three indices from baseline in both treatment groups. ADA was measured using the electrochemiluminescent methodology. Clinical responses, regardless of treatment groups, were examined in relation to the presence of the ADA. Results 250 patients with AS were treated with either CT-P13 or INX. Baseline comparability was demonstrated with each of these 3 indices. At week 54, BASDAI improved significantly from baseline in both treatment groups (CT-P13: from 6.74 to 3.78 and INX: from 6.57 to 3.70) and this improvement was similar between groups (difference of means -0.29; CI of the difference -0.91 to 0.32). BASFI and BASMI also improved in similar pattern: BASFI (CT-P13: from 6.20 to 3.42 and INX: from 6.24 to 3.46) and BASMI (CT-P13: from 4.0 to 2.8 and INX: from 4.1 to 3.2). At week 54, 50% improvement of the baseline BASDAI (BASDAI50) was achieved in 44.3% for CT-P13 and 46.3% for INX and BASDAI50 response rate was comparable between the two groups (p=0.7737). Overall, no statistical significance in clinical responses between the treatment groups at week 54 was found for all indices. Higher ASAS20/40 responses were seen in the ADA negative patients (72.7%/56.5%) compared with ADA positive patients (54.7%/37.7%) at week 54. Mean change from baseline for BASDAI and BASFI improved significantly in ADA negative subgroup than ADA positive subgroup (BASDAI: -3.13 vs. -2.30 and BASFI: -2.97 vs. -2.18) but no clear association with ADA was seen for BASMI. Conclusions Well-established indices of disease activity, disability and mobility in patients with AS were improved and statistically similar between CT-P13 and INX group. ASAS20/40, BASDAI and BASFI by ADA subgroup showed evidence of a relationship which was higher clinical responses in ADA negative subgroup. Disclosure of Interest W. Park Grant/research support: Celltrion, Consultant for: Celltrion, Speakers bureau: Celltrion, D. H. Yoo Grant/research support: Celltrion, Consultant for: Celltrion, Speakers bureau: Celltrion, S. Szantό: None declared, F. Berghea: None declared, M. Brzosko Grant/research support: Celltrion, P. Wiland Grant/research support: Celltrion, S. Smiyan Grant/research support: Celltrion, R. Araiza-Casillas Grant/research support: Celltrion, F. Diaz-Gonzalez Grant/research support: Celltrion, J. H. Suh Employee of: Celltrion DOI 10.1136/annrheumdis-2014-eular.3804" @default.
• W2315300447 created "2016-06-24" @default.
• W2315300447 creator A5002487560 @default.
• W2315300447 creator A5007364793 @default.
• W2315300447 creator A5012926852 @default.
• W2315300447 creator A5036599777 @default.
• W2315300447 creator A5045182020 @default.
• W2315300447 creator A5045684901 @default.
• W2315300447 creator A5051065833 @default.
• W2315300447 creator A5067011103 @default.
• W2315300447 creator A5072865266 @default.
• W2315300447 creator A5090693306 @default.
• W2315300447 date "2014-06-01" @default.
• W2315300447 modified "2023-10-18" @default.
• W2315300447 title "OP0157 Clinical Response of Disease Activity, Disability and Mobility Indices in Relation to Anti-Drug Antibody in the Planetas" @default.
• W2315300447 doi "https://doi.org/10.1136/annrheumdis-2014-eular.3804" @default.
• W2315300447 hasPublicationYear "2014" @default.
• W2315300447 type Work @default.
• W2315300447 sameAs 2315300447 @default.
• W2315300447 citedByCount "4" @default.
• W2315300447 countsByYear W23153004472015 @default.
• W2315300447 countsByYear W23153004472016 @default.
• W2315300447 countsByYear W23153004472017 @default.
• W2315300447 countsByYear W23153004472018 @default.
• W2315300447 crossrefType "journal-article" @default.
• W2315300447 hasAuthorship W2315300447A5002487560 @default.
• W2315300447 hasAuthorship W2315300447A5007364793 @default.
• W2315300447 hasAuthorship W2315300447A5012926852 @default.
• W2315300447 hasAuthorship W2315300447A5036599777 @default.
• W2315300447 hasAuthorship W2315300447A5045182020 @default.
• W2315300447 hasAuthorship W2315300447A5045684901 @default.
• W2315300447 hasAuthorship W2315300447A5051065833 @default.
• W2315300447 hasAuthorship W2315300447A5067011103 @default.
• W2315300447 hasAuthorship W2315300447A5072865266 @default.
• W2315300447 hasAuthorship W2315300447A5090693306 @default.
• W2315300447 hasConcept C126322002 @default.
• W2315300447 hasConcept C1862650 @default.
• W2315300447 hasConcept C2776260265 @default.
• W2315300447 hasConcept C2777138892 @default.
• W2315300447 hasConcept C2777402515 @default.
• W2315300447 hasConcept C2777453003 @default.
• W2315300447 hasConcept C2777575956 @default.
• W2315300447 hasConcept C2779134260 @default.
• W2315300447 hasConcept C2780415856 @default.
• W2315300447 hasConcept C59491497 @default.
• W2315300447 hasConcept C71924100 @default.
• W2315300447 hasConceptScore W2315300447C126322002 @default.
• W2315300447 hasConceptScore W2315300447C1862650 @default.
• W2315300447 hasConceptScore W2315300447C2776260265 @default.
• W2315300447 hasConceptScore W2315300447C2777138892 @default.
• W2315300447 hasConceptScore W2315300447C2777402515 @default.
• W2315300447 hasConceptScore W2315300447C2777453003 @default.
• W2315300447 hasConceptScore W2315300447C2777575956 @default.
• W2315300447 hasConceptScore W2315300447C2779134260 @default.
• W2315300447 hasConceptScore W2315300447C2780415856 @default.
• W2315300447 hasConceptScore W2315300447C59491497 @default.
• W2315300447 hasConceptScore W2315300447C71924100 @default.
• W2315300447 hasIssue "Suppl 2" @default.
• W2315300447 hasLocation W23153004471 @default.
• W2315300447 hasOpenAccess W2315300447 @default.
• W2315300447 hasPrimaryLocation W23153004471 @default.
• W2315300447 hasRelatedWork W1699840720 @default.
• W2315300447 hasRelatedWork W2073044510 @default.
• W2315300447 hasRelatedWork W2315300447 @default.
• W2315300447 hasRelatedWork W2482832580 @default.
• W2315300447 hasRelatedWork W2594476110 @default.
• W2315300447 hasRelatedWork W2967017096 @default.
• W2315300447 hasRelatedWork W3164497504 @default.
• W2315300447 hasRelatedWork W32850394 @default.
• W2315300447 hasRelatedWork W4213156464 @default.
• W2315300447 hasRelatedWork W4298138404 @default.
• W2315300447 hasVolume "73" @default.
• W2315300447 isParatext "false" @default.
• W2315300447 isRetracted "false" @default.
• W2315300447 magId "2315300447" @default.
• W2315300447 workType "article" @default.